Keywords: Sanofi, Isis Pharma, Genzyme, Kynamro, Cholesterol, HoFH, USA, FDA

FDA clears Sanofi and Isis' Kynamro for inherited cholesterol disorder

Article | 30 January 2013

Print This

The US Food and Drug Administration yesterday approved Sanofi (Euronext: SAN) subsidiary Genzyme’s orphan drug Kynamro (mipomersen sodium) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in